Latest Trials
| EudraCT Number: 2004-002871-18 | Sponsor Protocol Number: A-92-52030-166 | Start Date: 2006-02-09 | ||||||
| Sponsor Name: IPSEN PHARMA, S.A. | ||||||||
| Full Title: Phase II, open, single group,multicentre study to evaluate the efficacy and safety of Somatuline Autogel® (120 mg) administered every 4 weeks by deep subcutaneous injection in the tumour´s growth s... | ||||||||
| Medical condition: Patients with progressive neuroendocrine tumours who are not eligible to be treated with either surgery or chemotherapy | ||||||||
|
||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||
| Trial protocol: ES (Completed) | ||||||||
| Trial results: View results | ||||||||